TY - JOUR
T1 - Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project
AU - Doorduijn, Astrid S.
AU - de van der Schueren, Marian A. E.
AU - van de Rest, Ondine
AU - de Leeuw, Francisca A.
AU - Hendriksen, Heleen M. A.
AU - Teunissen, Charlotte E.
AU - Scheltens, Philip
AU - van der Flier, Wiesje M.
AU - Visser, Marjolein
N1 - Funding Information:
PS has served as consultant for Wyeth-Elan, Genentech, Danone, and Novartis. CT is a member of the Innogenetics International Advisory Boards of Fujirebio/Innogenetics and Roche. Research programs of WvdF have been funded by ZonMw , NWO , EU-FP7 , EU-JPND , Alzheimer Nederland , CardioVascular Onderzoek Nederland , Health∼Holland , Topsector Life Sciences and Health , stitching Dioraphte , Gieskes-Strijbis fonds , stichting Equilibrio , Pasman stichting , Biogen MA Inc , Boehringer Ingelheim , Life-MI , AVID , Roche BV , Janssen Stellar , Combinostics . WvdF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WvdF has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding was paid to her institution.
Funding Information:
The NUDAD project is funded by NWO-FCB (project number 057-14-004) and AD, FdL and HH are appointed on this project.PS has served as consultant for Wyeth-Elan, Genentech, Danone, and Novartis. CT is a member of the Innogenetics International Advisory Boards of Fujirebio/Innogenetics and Roche. Research programs of WvdF have been funded by ZonMw, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health?Holland, Topsector Life Sciences and Health, stitching Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Janssen Stellar, Combinostics. WvdF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WvdF has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding was paid to her institution.Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. WvdF holds the Pasman chair. WvdF is recipient of a NWO-FCB grant for the NUDAD project (#057-14-004). The NUDAD project is funded by NWO-FCB (project number 057-14-004) and AD, FdL and HH are appointed on this project. WvdF is recipient of a donation by stichting Equilibrio, and of a ZonMW Memorabel grant (#733050814).
Funding Information:
Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds . The clinical database structure was developed with funding from Stichting Dioraphte . WvdF holds the Pasman chair. WvdF is recipient of a NWO-FCB grant for the NUDAD project (#057-14-004). The NUDAD project is funded by NWO-FCB (project number 057-14-004) and AD, FdL and HH are appointed on this project. WvdF is recipient of a donation by stichting Equilibrio, and of a ZonMW Memorabel grant ( #733050814 ).
Publisher Copyright:
© 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Objective: In cognitively normal adults, nutritional parameters are related to cognitive decline and incidence of dementia. Studies on the role of nutrition in predementia stages subjective cognitive decline and mild cognitive impairment, and mild stages of Alzheimer's disease (AD) dementia in a clinical setting are lacking. In the absence of a curative treatment, this evidence is important for targeting nutritional factors to potentially prevent or delay further cognitive decline. Our aim is to investigate associations of nutritional parameters with clinical progression in patients ranging from those who are cognitively normal to those who have AD dementia. Design: Longitudinal. Setting and Participants: Memory clinic, 551 patients (219 with subjective cognitive decline, 135 with mild cognitive impairment, and 197 with AD dementia), mean age 64 ± 8 years. Measurements: We assessed body mass index, fat-free mass, Mini-Nutritional Assessment, and dietary intake with the Dutch Healthy Diet food frequency questionnaire and the 238-item healthy life in an urban setting (HELIUS) food frequency questionnaire at baseline. Cox proportional hazard models were used to evaluate associations of nutritional parameters with clinical progression. Additional analyses were restricted to patients who were amyloid positive. Results: We observed clinical progression in 170 patients (31%) over 2.2 ± 0.9 years. Poorer Mini-Nutritional Assessment score [hazard ratio (95% confidence interval) 1.39 (1.18–1.64)], lower body mass index [1.15 (0.96–1.38)], lower fat-free mass [1.40 (0.93–2.10)], and a less healthy dietary pattern [1.22 (1.01–1.48)] were associated with a higher risk of clinical progression. Similar effect sizes were found in patients who were amyloid positive. Conclusions and Implications: Poorer nutritional status and a less healthy dietary pattern are associated with a higher risk of clinical progression. This study provides support for investigating whether improving nutritional status can alter the clinical trajectory of AD.
AB - Objective: In cognitively normal adults, nutritional parameters are related to cognitive decline and incidence of dementia. Studies on the role of nutrition in predementia stages subjective cognitive decline and mild cognitive impairment, and mild stages of Alzheimer's disease (AD) dementia in a clinical setting are lacking. In the absence of a curative treatment, this evidence is important for targeting nutritional factors to potentially prevent or delay further cognitive decline. Our aim is to investigate associations of nutritional parameters with clinical progression in patients ranging from those who are cognitively normal to those who have AD dementia. Design: Longitudinal. Setting and Participants: Memory clinic, 551 patients (219 with subjective cognitive decline, 135 with mild cognitive impairment, and 197 with AD dementia), mean age 64 ± 8 years. Measurements: We assessed body mass index, fat-free mass, Mini-Nutritional Assessment, and dietary intake with the Dutch Healthy Diet food frequency questionnaire and the 238-item healthy life in an urban setting (HELIUS) food frequency questionnaire at baseline. Cox proportional hazard models were used to evaluate associations of nutritional parameters with clinical progression. Additional analyses were restricted to patients who were amyloid positive. Results: We observed clinical progression in 170 patients (31%) over 2.2 ± 0.9 years. Poorer Mini-Nutritional Assessment score [hazard ratio (95% confidence interval) 1.39 (1.18–1.64)], lower body mass index [1.15 (0.96–1.38)], lower fat-free mass [1.40 (0.93–2.10)], and a less healthy dietary pattern [1.22 (1.01–1.48)] were associated with a higher risk of clinical progression. Similar effect sizes were found in patients who were amyloid positive. Conclusions and Implications: Poorer nutritional status and a less healthy dietary pattern are associated with a higher risk of clinical progression. This study provides support for investigating whether improving nutritional status can alter the clinical trajectory of AD.
KW - Malnutrition
KW - dementia
KW - food intake
KW - mild cognitive impairment
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85096930419&partnerID=8YFLogxK
U2 - 10.1016/j.jamda.2020.10.020
DO - 10.1016/j.jamda.2020.10.020
M3 - Article
C2 - 33239240
SN - 1525-8610
JO - Journal of the American Medical Directors Association
JF - Journal of the American Medical Directors Association
ER -